# Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

> **NCT00620815** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 601 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine
- **BIOLOGICAL:** Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1
- **BIOLOGICAL:** Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine
- **BIOLOGICAL:** Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1
- **BIOLOGICAL:** Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
- **BIOLOGICAL:** MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine

## Key facts

- **NCT ID:** NCT00620815
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-12
- **Target enrollment:** 601 (ACTUAL)
- **Last updated:** 2016-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620815, "Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00620815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*